These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Mechanisms of allo-recognition. Recognition by in vivo-primed T cells of specific major histocompatibility complex polymorphisms presented as peptides by responder antigen-presenting cells.
    Author: Watschinger B, Gallon L, Carpenter CB, Sayegh MH.
    Journal: Transplantation; 1994 Feb 27; 57(4):572-6. PubMed ID: 8116044.
    Abstract:
    There is evidence of two pathways of allorecognition, the direct pathway where T cells recognize intact allo-MHC molecules on the surface of target cells, and the indirect pathway where T cells recognize processed allo-MHC presented by self antigen-presenting cells. We used synthetic class II MHC allopeptides to study the cellular mechanisms of the indirect allorecognition pathway and its potential role in vascularized allograft rejection. LEW (RT1l) rat T cells--which are primed by immunization with a mixture of four 25 mer class II MHC allopeptides, representing the full length sequence of the beta chain of the hypervariable domain of the RT1.Du (WF), or by primary WF (RT1u) vascularized cardiac allografts--were capable of recognizing and proliferating to specific polymorphic class II MHC sequences when presented as peptides by responder APCs. T cells from naive LEW animals, WF animals immunized with syngeneic RT1.Du beta peptides, or LEW recipients of third-party BN (RT1n) vascularized cardiac allografts did not proliferate to the RT1.Du beta peptides, indicating the specificity of allopeptide recognition. In the strain combination used, immunogenicity of class II MHC allopeptides is determined by factors other than polymorphisms alone, since epitopic differences in 2 of the 4 RT1.Du beta allopeptides were not immunogenic. Responder T cells were CD4+, and were inhibited by monomorphic anticlass II monoclonal antibodies, and by specific anticlass II alloantibodies. These observations confirm the occurrence of self MHC-restricted recognition of processed allo-MHC in primary vascularized allograft rejection, and provide the rationale to develop novel and specific immunotherapies in organ transplantation.
    [Abstract] [Full Text] [Related] [New Search]